Yun Joon Jung
Director of Biology Judo Bio
Yun Joon Jung, PhD is Director of Biology at Judo Bio, where he leads nonclinical biology supporting the development of RNA-based therapeutics.
Previously, Dr. Jung held scientific roles at CAMP4 Therapeutics, where he led the Urea Cycle Disorder program and helped advance CMP-CPS-001, an antisense oligonucleotide therapeutic, into clinical development.
Dr. Jung completed his postdoctoral training at Boston Children’s Hospital and Harvard Medical School and earned his PhD from the University of California, Davis, and MS from the University of California, Berkeley.
Seminars
Wednesday 18th March 2026
Precision siRNA Delivery to the Proximal Tubule via Endogenous Receptor Targeting
1:00 pm
- Leverage endogenous receptor-mediated uptake (via megalin) to deliver ligand-siRNA conjugates directly into proximal tubule cells for high kidney exposure and gene silencing
- Achieve durable target gene knockdown (50–70%) in the kidney lasting up to four weeks from a single dose— demonstrating effectiveness of the receptor-mediated delivery strategy
- Overcome a longstanding delivery challenge by increasing siRNA accumulation in the kidney 5–30-fold compared to naked siRNA, enabling new therapeutic targets to be addressed
Wednesday 18th March 2026
Panel Discussion: How Can Novel Modalities be Used to Meet the Unmet Needs in CKD?
10:30 am
- Balancing innovation with clinical feasibility and scalable development in kidney disease
- Addressing AAV’s narrow tropism: how do we translate promise into real-world therapies?
- Exploring whether targeted delivery strategies must be disease-specific to maximize impact
- Ensuring RNAi and oligonucleotide therapies achieve durable, clinically meaningful kidney knockdown
